ECL Finance Limited (Revised)

November 17, 2025

Facilities/Instruments	Amount (₹ crore)	Rating[1]	Rating Action
Long-term bank facilities	3,256.66	CARE A; Stable	Reaffirmed
Subordinate debt	112.00	CARE A; Stable	Assigned
Subordinate debt	360.00 (Reduced from 380.00)	CARE A; Stable	Reaffirmed
Subordinate debt	45.00	CARE A; Stable	Reaffirmed
Non-convertible debentures	100.00	CARE A; Stable	Assigned
Non-convertible debentures	62.50 (Reduced from 127.00)	CARE A; Stable	Reaffirmed
Non-convertible debentures	11.30	CARE A; Stable	Reaffirmed
Non-convertible debentures	175.20	CARE A; Stable	Reaffirmed
Subordinate debt	-	-	Withdrawn

Details of instruments/facilities in Annexure-1.

Rationale and key rating drivers

CARE Ratings Limited (CareEdge Ratings) has taken a consolidated view of Edelweiss Financial Services Limited (EFSL) and its subsidiaries for rating its debt instruments and facilities. Reaffirmation of ratings reflects the group's diversified business presence resulting in income diversification, adequate capitalisation, run-down in the wholesale credit book, demonstrated ability of the group to monetise stake across businesses and adequate liquidity. However, the rating remains constrained by uncertainty in recoveries from stressed wholesale assets leading to asset quality challenges, relatively higher cost and limited diversification in debt funding, moderate profitability, relatively lower proportion of retail assets in lending book.

The group's diversified businesses spanning across credit, asset management, asset reconstruction (ARC), alternative investments, and insurance, continues to support ratings. The group has been able to monetise stakes in businesses such as asset reconstruction, insurance broking, wealth management, in the last few years. In FY25, the group divested 14% stake in Nuvama Wealth Management for ~₹3,200 crore and the group has announced planned sale of a 15% stake in Edelweiss Mutual Fund to Westbridge Capital for ₹450 crore by March 2026, will strengthen liquidity. The group intends to unlock value through stake sales, including monetisation of its housing finance arm, Nido Home Finance Limited and a planned 10–15% divestment in Edelweiss Alternative Asset Management (EAAA) through its expected IPO in Q1FY26. The group's ability to execute these divestments to reduce holding company debt will be a key rating monitorable.

The group's capitalisation remains adequate with tangible net worth of ₹4,272 crore, and the net debt across group has reduced to ₹10,921 crore as on June 30, 2025, from ₹13,090 crore as on March 31,2024. In FY25 and Q1FY26, the group raised debt of ₹4,392 crore and ₹1,367 crore, respectively. In the last few years, the group raised majority debt funds through public issues of non-convertible debentures and structured products and recently, the credit entities have been able to raise fresh funds from banks. The group's ability to diversify its funding sources at competitive rates will remain a key monitorable.

As on June 30, 2025, the group's liquidity stood at ₹4,834 crore, comprising ₹2,926 crore in cash/bank balances, ₹192 crore in bank lines, and ₹1,716 crore in treasury assets. The overnight liquidable assets in the form of cash/bank balances of ₹2,926 crore are sufficient to meet eight months of obligations without relying on business inflows. With reduction in overall debt of the group, CareEdge Ratings notes decline in annual debt repayment obligations to ~₹4,500 crore from above ₹9,000 crore in prior years.

In the last five years, the group has exited its wholesale credit business but continues to face asset quality issues with residual assets. A large portion of loans was sold to ARCs and Alternate Investment Fund(AIFs), often through subordinated structures, with EFSL retaining risk and put options in some deals. Despite a reduction in stressed wholesale assets from ₹9,597 crore (March

[1]Complete definition of ratings assigned are available at www.careratings.com and other CARE Ratings Limited's publications.

31, 2024) to ₹7,833 crore (June 30, 2025), and recoveries of ~₹2,000 crore in FY25, the stressed wholesale asset levels remain elevated. Recovery remains critical due to uncertain cashflows, even though adequate provisions have been maintained. As on June 30, 2025, net stressed assets stood at ₹4,337 crore. The group's ability to recover the stressed wholesale assets as planned would be a key monitorable.

The retail lending assets under management (AUM) witnessed a slight decline to ₹5,345 crore as on June 30, 2025, compared to ₹5,368 crore as on March 31, 2024, driven by slowdown in Micro small and medium enterprises (MSME) disbursements. With recent changes in leadership team in lending business, CareEdge Ratings expects branch-led expansion of the MSME business to supplement co-lending in MSME and housing finance.

The group is expected to reduce the corporate debt by monetisation of its investments, focus on recovery of the stressed assets, and grow its retail lending business while maintaining adequate liquidity.

CareEdge Ratings has withdrawn the rating assigned to subordinate debt on redemption due to maturity and is in line with CareEdge Ratings' withdrawal policy.

Rating sensitivities: Factors likely to lead to rating actions

Positive factors: Factors that could individually or collectively lead to positive rating action/upgrade:

- Significant scale up in retail lending businesses with return on total AUM of over 2.5% on a sustained basis.
- Significant reduction in stressed wholesale assets without impacting net worth.
- Significant improvement in group profitability.

Negative factors: Factors that could individually or collectively lead to negative rating action/downgrade:

- Slower-than-expected reduction in consolidated debt from recoveries from wholesale assets or inability to monetise group's businesses worth ~₹2,400 crore by September 2026.
- Deterioration in group profitability or asset quality.
- Significant depletion in liquidity buffer (cash and bank balances) maintained by the group.

Analytical approach: Consolidated
As the flagship company of the Edelweiss group, EFSL owns 100% of most of its subsidiaries and the management/line functions of these businesses are common, with significant operational and financial integration among them. Hence, CareEdge Ratings has considered a consolidated view of EFSL to arrive at the rating. Subsidiaries considered for consolidation are listed under Annexure-6.

Outlook: Stable

The stable outlook reflects the group's ability to reduce debt by monetising its investments in subsidiaries, sustain recoveries from stressed wholesale assets, while maintaining adequate liquidity.

Detailed description of key rating drivers:

Key strengths

Diversified presence across business segments
Edelweiss Group is a diversified financial services conglomerate with operations spanning credit, asset management, advisory, and insurance. Its credit portfolio includes mortgage financing and SME lending, while advisory and fee-based businesses comprise asset management (alternative, asset reconstruction, and mutual funds).

The group has demonstrated consistent growth in its asset management segment (alternative and mutual funds), with AUM rising to ₹215,170 crore as on June 30, 2025, from ₹201,440 crore in March 2025 and ₹181,700 crore in March 2024.

In the distressed asset space, Edelweiss Asset Reconstruction Company Limited (EARC) is among the largest private ARCs in India, managing ₹12,267 crore in security receipts as of June 30, 2025. The decline from ₹31,590 crore in March 2024 was primarily driven by write-offs in the 5:95 book, which had completed over eight years. Recoveries stood at ₹4,753 crore in Q1FY26, driven by resolutions of large account. EARC is now shifting focus to retail assets, which comprise 18% of its AUM.

In lending, the group is focussing on housing finance and micro small and medium enterprise (MSME) loans via co-lending partnerships with banks. The wholesale legacy exposures will continue to reduce as the company is not undertaking new wholesale lending in non-banking financial company (NBFC). Its NBFC arm is expected to expand MSME lending through branch networks, supported by bank funding.

The group also offers life and general insurance products. The management expects the insurance businesses to break even by FY27.

For FY25, Edelweiss reported consolidated income of ₹9,327 crore, with net gains from fair value changes contributing 32%, interest income contributing 29%, broking and fee-based income 12%, and insurance premium income rising to 28% from 12% in FY21.

Adequate capitalisation, relatively high gearing

As on March 31, 2025, the group remained adequately capitalised, supported by monetisation of stakes in recent years. The consolidated tangible net worth (TNW) stood at ₹4,272 crore, down from ₹4,770 crore as on March 31, 2024, primarily due to application of IRAC norms to security receipts held by ECL Finance Limited, as the company had high capital adequacy ratio. As on March 31, 2025, consolidated gearing (gross debt/TNW) remained at 4.18x, aided by a reduction in gross debt, which declined to ₹17,875 crore from ₹19,988 crore as on March 31,2024. Considering the liquidity held, net debt reduced to ₹10,921 crore as on June 30, 2025, from ₹13,090 crore as on March 31, 2024.

In FY25 and Q1FY26, the group raised ₹4,392 crore and ₹1,367 crore, respectively, through capital markets and banks. While earlier funding was largely through public issuances of NCDs and structured products, the group has recently been able to attract bank funding. The group's ability to diversify funding sources at competitive rate remains a key monitorable.

CareEdge Ratings notes that the group benefits from business diversification, enabling value unlocking when required from time to time. Going forward, the group's ability to maintain adequate capitalisation, avoid further net worth erosion from stressed wholesale assets, and execute planned stake monetisations will be key monitorable.

Experienced management team

EFSL is supported by a seasoned and stable senior management team with extensive experience in the financial sector. Most senior leaders have been with the company for a significant duration, contributing to continuity and strategic consistency. CareEdge Ratings notes that each business vertical—ARC, Asset Management (AMC), Alternatives, Credit, and Insurance—is led by strong and capable management teams.

Demonstrated track record of monetisation of investments in subsidiaries

The group has demonstrated its ability to monetise investments in subsidiaries to strengthen its capital position. In FY25, the group divested ~13% stake in Nuvama Wealth Management Limited for ~₹3,200 crore. The group plans to further monetise its holdings by divesting 10–20% stake in EAAA through an IPO, expected to raise ~₹1,500 crore, with the Draft Red Herring Prospectus (DRHP) to be refiled with Securities and Exchange Board of India (SEBI) by November 2025. Additionally, a 15% stake in Edelweiss Mutual Fund is planned to be sold to Westbridge Capital for ₹450 crore by March 2026. The group also intends to divest its stake in the housing finance subsidiary. The group has raised ~₹7,900 crore till date through stake sales in businesses, such as NBFC, ARC, insurance broking, and wealth management.

CareEdge Ratings estimates that these monetisation efforts could generate ~₹2,400 crore by September 2026. The proceeds from these divestments are expected to be utilised primarily for debt reduction at the holding company level.

Key weaknesses

Profitability led by asset management business amid diversification

On a consolidated basis, Edelweiss Group's profitability remains moderate, supported by insurance premiums, net fair value gains, and interest income. In FY25, the group reported a profit after tax (PAT) of ₹536 crore, up from ₹528 crore in FY24, driven by lower credit costs and higher insurance premium income. Return on total assets (ROTA) and return on tangible net worth (RONW)

improved to 1.33% and 11.85% in FY25, from 1.26% and 8.7% in FY24, respectively. In Q1FY26, PAT rose to ₹103 crore from ₹85 crore in Q1 FY25, despite lower total income, due to reduced expenses.

All business segments are profitable except insurance. Asset management businesses—ARC, alternatives, and mutual funds—are the primary contributors, accounting for ~94% of consolidated profit (excluding insurance). Credit business profitability remains subdued due to slower retail growth. Life insurance business reported a positive PAT in Q4FY25 and Q1FY26, and Life and General Insurance businesses are on track to achieve break-even by FY27.

Going forward, sustaining profitability from asset management, improving credit business performance through growth and controlled credit costs, and avoiding further losses from residual wholesale assets will be key rating monitorables.

Asset quality challenges despite moderate recoveries

As on March 31, 2025, Edelweiss Group's lending business reported a Gross Stage 3 (GS3) asset of 7.9%, down from 13.0% as on March 31, 2024, reflecting recoveries in the wholesale loan segment. Net Stage 3 (NS3) assets declined to 2.7% from 3.1% over the same period. As on June 30, 2025, GS3 and NS3 rose slightly to 8.4% and 2.9%, respectively. In the retail portfolio, GS3 and NS3 stood at 2.9% and 2.0%, respectively, as on June 30, 2025, compared to 2.6% and 1.9% on March 31, 2025, and 1.8% and 1.2% on March 31, 2024. The increase was attributed to slower growth in retail AUM, despite stable absolute GS3 levels.

The group has significantly downsized its wholesale book through recoveries and asset sell-downs to ARCs and AIFs. Stage 3 assets retained at the consolidated level, including those with put options, declined to ₹7,833 crore as on June 30, 2025, from ₹7,971 crore on March 31, 2025, and ₹9,597 crore on March 31, 2024. The group witnessed annual cash recoveries of ~₹2,000 crore ended June 30, 2025. However, the high residual portfolio continues to pose cash flow challenges. The group has created adequate provisioning on these stressed assets over the years. Net Stage 3 assets retained at consolidated level, reduced to ₹4,337 crore as on June 30, 2025 from ₹4,575 crore as on March 31, 2025 and ₹5,497 crore as on March 31, 2024.
On a consolidated basis, EFSL reported GS3 [(including purchase and originated credit impaired (POCI)] and NS3 at 68.3% and 37.5%, respectively, as on March 31, 2025, compared to 73.5% and 42.6% as on March 31,2024.

CareEdge Ratings notes that the group's ability to further reduce the residual book through recoveries, without incurring additional provisioning, remains a key rating monitorable.

Lower growth in retail AUM, despite improvement

As on June 30, 2025, Edelweiss Group's overall loan book (excluding portfolio recourse to the parent) was ₹5,081 crore, down from ₹5,246 crore on March 31, 2025, and ₹5,537 crore on March 31, 2024. The retail segment, which includes housing finance, loans against property, construction finance, SME loans, and business loans, had a loan book of ₹4,011 crore on June 30, 2025, down from ₹4,080 crore on March 31, 2025, and ₹4,261 crore on March 31, 2024, due to focus on asset light model through co-lending partnerships. Retail AUM (including co-lending and securitisation) stood at ₹5,345 crore as on June 30, 2025 compared to ₹5,378 crore as on March 31, 2025 and ₹5,368 crore as on March 31, 2024.

Despite the focus on co-lending, the retail AUM has not seen substantial growth over the last two years due to cautious disbursements by the NBFC, in FY25. However, the housing finance disbursements reported 33% growth in FY25. With recent changes in leadership team in NBFC, CareEdge Ratings expects branch-led expansion of the MSME business to supplement co-lending.

Liquidity: Adequate

The liquidity profile of the group remains adequate. As on August 01, 2025, the group had liquidity to the tune of ~₹5,000 crore. As on June 30, 2025, the group's liquidity stood at ₹4,834 crore comprising overnight liquidable assets of ₹2,926 crore, treasury assets of ₹1,716 crore and available bank lines of ₹192 crore. The overnight liquidable assets in the form of cash/bank balances of ₹2,926 crore are sufficient to meet eight months of obligations without relying on business inflows. The liquidity buffer has increased in FY25 supported by sale of Nuvama stake. CareEdge Ratings also notes that the annual debt repayment obligation of the group has reduced to ~₹4,500 crore from ~₹9,000 crore in the prior years. CareEdge Ratings expects the group to always maintain liquidity of ~₹4,000 crore, going forward.

However, uncertainty exists on timeliness of inflows due to exposure to relatively weaker asset profile in its wholesale credit book and recovery timeline of sticky stressed assets.

Environment, social, and governance risks

Although Edelweiss's service-oriented business model limits its direct exposure to environmental risks, credit risk may arise if operations of any asset class in the portfolio are adversely impacted by environmental factors.

Social risks in the form of cybersecurity threats, customer data breaches, or mis-selling practices can affect Edelweiss's regulatory compliance and reputation and hence remain a key monitorable. Through its EdelGive Foundation, Edelweiss is committed to addressing social and economic inequalities that prevent women and girls from achieving their full potential. Initiatives include support for gender equality issues, financial literacy programmes, grassroots leadership development, and assistance to survivors of domestic and sexual violence. EdelGive has also launched programmes, such as GROW+ and conducted a Landscape Study on Women Entrepreneurship, among others, which have strengthened Edelweiss's position within the ESG framework.

Edelweiss's Board comprises seven Directors, including four Independent Directors and two female Directors. The company has adopted a strong investor grievance redressal system. No grievances were received from shareholders, while 222 grievances were received from bondholders, all of which were suitably addressed. Edelweiss continues to focus on enhancing the quality of disclosures to investors and analysts through benchmarking with peers.

Applicable criteria

Consolidation
Definition of Default
Rating Outlook and Rating Watch
Financial Ratios - Financial Sector
Withdrawal Policy
Non Banking Financial Companies

About the company and industry

Industry classification

Macroeconomic indicator	Sector	Industry	Basic industry
Financial services	Financial services	Finance	Non-banking financial company (NBFC)

ECL Finance Limited

ECL Finance, incorporated in July 2005 and registered with the RBI as a non-deposit taking non-banking financial company, is a wholly owned subsidiary of the Edelweiss Group. Classified as a systemically important middle-layer NBFC, it focuses on secured retail loans mainly MSME finance. As part of the Group's initiative to simplify its lending businesses, Edelweiss Retail Finance Limited (ERFL) was amalgamated into ECL Finance, with the scheme becoming effective on September 30, 2025.

Edelweiss Financial Services Limited

Previously known as Edelweiss Capital Limited, EFSL was incorporated in 1995 by Rashesh Shah and Venkat Ramaswamy. EFSL is registered as a Category I Merchant Banker with SEBI and is the holding company of the Edelweiss Group. On a standalone basis, the company is primarily engaged in investment banking services and provides development, managerial, and financial support to the businesses of the Edelweiss group entities. The Edelweiss Group offers a range of products and services, spanning varied asset classes and diversified consumer segments. The Edelweiss Group has seven key businesses: Alternatives, Asset Management, Asset Reconstruction, SME Lending, Housing Finance, and Insurance comprising both Life and General Insurance. In addition, the Treasury management attends to the balance sheet and liquidity management of the group. EFSL, the parent company, has 26 subsidiaries as on March 31, 2025. EFSL has 255 offices within 136 cities serving 103 lakh+ customers. The company has an employee strength of 5,769, as on March 31, 2025, with women comprising 25% of employee base.

Brief Financials -EFSL Consolidated (₹ crore)	31-03-2024	31-03-2025	Q1FY26
	A	A	UA
Total income	9,602	9,519	2,281
PAT	528	536	103
Interest coverage (times)	1.16	1.32	1.16
Total assets**	41,175	39,636	NA
Net NPA for credit book entities (%)	2.56	2.67	2.93
ROTA (%)	1.26	1.33	NA

A: Audited UA: Unaudited; Note: these are latest available financial results;
*Based on CareEdge Ratings' calculation, adjusted for deferred tax assets and intangible assets; NA: Not Available

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for last three years: Annexure-2

Detailed explanation of covenants of rated instrument / facility: Annexure-3

Complexity level of instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned and Rating Outlook
Debentures-Non-convertible debentures	Proposed	-	-	-	43.60	CARE A; Stable
Debentures-Non-convertible debentures	INE804IA7253	28-Nov-2019	NA	28-Nov-2029	40.50	CARE A; Stable
Debentures-Non-convertible debentures	INE804IA7246	28-Nov-2019	NA	28-Nov-2029	49.00	CARE A; Stable
Debentures-Non-convertible debentures	INE804IA7147	23-May-2019	NA	23-May-2029	6.60	CARE A; Stable
Debentures-Non-convertible debentures	INE804IA7238	28-Nov-2019	NA	28-Nov-2024	0.00	Withdrawn
Debentures-Non-convertible debentures	INE804IA7220	28-Nov-2019	NA	28-Nov-2024	0.00	Withdrawn

Debentures-Non-convertible debentures	INE804IA7139	23-May-2019	NA	23-May-2029	35.50	CARE A; Stable
Debentures-Non-convertible debentures	Proposed	-	-	-	11.30	CARE A; Stable
Debentures-Non-convertible debentures	INE804IA7188	28-Nov-2019	NA	28-Nov-2024	0.00	Withdrawn
Debentures-Non-convertible debentures	INE804IA7212	28-Nov-2019	NA	28-Nov-2024	0.00	Withdrawn
Debentures-Non-convertible debentures	Proposed	-	-	-	24.70	CARE A; Stable
Debentures-Non-convertible debentures	INE804I07H49	22-Dec-2015	9.80%	22-Dec-2025	25.00	CARE A; Stable
Debentures-Non-convertible debentures	INE804I07E42	06-Oct-2015	9.81%	06-Oct-2025	0.00	Withdrawn
Debentures-Non-convertible debentures	INE804I07E34	05-Oct-2015	9.80%	03-Oct-2025	0.00	Withdrawn
Debentures-Non-convertible debentures	INE804I07ZY4	21-Apr-2015	10.00%	21-Apr-2025	0.00	Withdrawn
Debentures-Non-convertible debentures	INE804I07ZT4	28-Mar-2015	10.20%	28-Mar-2025	0.00	Withdrawn
Debentures-Non-convertible debentures	INE804I07ZE6	16-Feb-2015	10.10%	14-Feb-2025	0.00	Withdrawn
Debentures-Non-convertible debentures	INE804I08684	03-May-2016	9.50%	28-Apr-2026	11.00	CARE A; Stable
Debentures-Non-convertible debentures	INE804I07H64	23-Dec-2015	9.60%	19-Dec-2025	1.00	CARE A; Stable
Debentures-Non-	INE804I07J05	19-Jan-2016	9.60%	13-Jan-2026	0.80	CARE A; Stable

convertible debentures						
Debentures-Non-convertible debentures	INE804I07E00	18-Sep-2015	9.75%	12-Sep-2025	0.00	Withdrawn
Debentures-Non-convertible debentures	Proposed	-	-	-	100.00	CARE A; Stable
Debt-Subordinate Debt	INE528S08027	10-Oct-2016	9.95%	09-Oct-2026	12.00	CARE A; Stable
Debt-Subordinate Debt	Proposed	-	-	-	100.00	CARE A; Stable
Debt-Subordinate Debt	Proposed	-	-	-	55.00	CARE A; Stable
Debt-Subordinate Debt	INE804I08759	13-Jun-2017	9.65%	08-Jun-2027	10.00	CARE A; Stable
Debt-Subordinate Debt	INE804I08726	05-May-2017	9.75%	30-Apr-2027	45.00	CARE A; Stable
Debt-Subordinate Debt	INE804I08692	16-Jun-2016	10.15%	16-Jun-2026	250.00	CARE A; Stable
Debt-Subordinate Debt	INE804I08676	30-Sep-2015	10.60%	30-Sep-2025	0.00	Withdrawn
Debt-Subordinate Debt	INE804I08668	03-Sep-2015	10.62%	03-Sep-2025	0.00	Withdrawn
Debt-Subordinate Debt	Proposed	-	-	-	45.00	CARE A; Stable
Debt-Subordinate Debt	INE804I08767	14-Jun-2017	9.60%	13-Jun-2025	0.00	Withdrawn
Debt-Subordinate Debt	INE804I08643	04-Feb-2015	11.25%	03-May-2025	0.00	Withdrawn
Fund-based-Long Term	-	-	-	31-Mar-2028	2757.07	CARE A; Stable
Fund-based-Long Term	Proposed	-	-	-	499.59	CARE A; Stable

Annexure-2: Rating history for last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2025-2026	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022-2023
1	Debt-Subordinate Debt	LT	-	-	-	-	-	1)Withdrawn (06-Oct-22)
2	Fund-based-Long Term	LT	2757.07	CARE A; Stable	-	1)CARE A; Stable (11-Feb-25) 2)CARE A (RWN) (08-Oct-24) 3)CARE A (RWN) (06-Jun-24)	1)CARE A; Stable (03-Jan-24) 2)CARE A+; Negative (05-Oct-23) 3)CARE A+; Negative (16-May-23)	1)CARE A+; Negative (06-Oct-22)
3	Debt-Subordinate Debt	LT	360.00	CARE A; Stable	-	1)CARE A; Stable (11-Feb-25) 2)CARE A (RWN) (08-Oct-24) 3)CARE A (RWN) (06-Jun-24)	1)CARE A; Stable (03-Jan-24) 2)CARE A+; Negative (05-Oct-23) 3)CARE A+; Negative (16-May-23)	1)CARE A+; Negative (06-Oct-22)
4	Commercial Paper-Commercial Paper (Standalone)	ST	-	-	-	1)Withdrawn (08-Oct-24) 2)CARE A1 (RWN) (06-Jun-24)	1)CARE A1 (03-Jan-24) 2)CARE A1+ (05-Oct-23) 3)CARE A1+	1)CARE A1+ (06-Oct-22)

							(16-May-23)	
5	Debentures-Non-convertible debentures	LT	62.50	CARE A; Stable	-	1)CARE A; Stable (11-Feb-25) 2)CARE A (RWN) (08-Oct-24) 3)CARE A (RWN) (06-Jun-24)	1)CARE A; Stable (03-Jan-24) 2)CARE A+; Negative (05-Oct-23) 3)CARE A+; Negative (16-May-23)	1)CARE A+; Negative (06-Oct-22)
6	Debentures-Market Linked Debentures	LT	-	-	-	1)Withdrawn (08-Oct-24) 2)CARE PP-MLD A (RWN) (06-Jun-24)	1)CARE PP-MLD A; Stable (03-Jan-24) 2)CARE PP-MLD A+; Negative (05-Oct-23) 3)CARE PP-MLD A+; Negative (16-May-23)	1)CARE PP-MLD A+; Negative (06-Oct-22)
7	Debt-Subordinate Debt	LT	45.00	CARE A; Stable	-	1)CARE A; Stable (11-Feb-25) 2)CARE A (RWN) (08-Oct-24) 3)CARE A (RWN) (06-Jun-24)	1)CARE A; Stable (03-Jan-24) 2)CARE A+; Negative (05-Oct-23) 3)CARE A+; Negative (16-May-23) 4)CARE D	1)CARE A+; Negative (06-Oct-22)

							(16-May-23)	
8	Fund-based-Long Term	LT	499.59	CARE A; Stable	-	1)CARE A; Stable (11-Feb-25) 2)CARE A (RWN) (08-Oct-24) 3)CARE A (RWN) (06-Jun-24)	1)CARE A; Stable (03-Jan-24) 2)CARE A+; Negative (05-Oct-23) 3)CARE A+; Negative (16-May-23)	1)CARE A+; Negative (06-Oct-22)
9	Commercial Paper-Commercial Paper (IPO Financing)	ST	-	-	-	1)Withdrawn (08-Oct-24) 2)CARE A1 (RWN) (06-Jun-24)	1)CARE A1 (03-Jan-24) 2)CARE A1+ (05-Oct-23) 3)CARE A1+ (16-May-23)	1)CARE A1+ (06-Oct-22)
10	Debentures-Non-convertible debentures	LT	11.30	CARE A; Stable	-	1)CARE A; Stable (11-Feb-25) 2)CARE A (RWN) (08-Oct-24) 3)CARE A (RWN) (06-Jun-24)	1)CARE A; Stable (03-Jan-24) 2)CARE A+; Negative (05-Oct-23) 3)CARE A+; Negative (16-May-23)	1)CARE A+; Negative (06-Oct-22)
11	Debentures-Non-convertible debentures	LT	175.20	CARE A; Stable	-	1)CARE A; Stable (11-Feb-25) 2)CARE A (RWN) (08-Oct-24)	1)CARE A; Stable (03-Jan-24)	1)CARE A+; Negative (06-Oct-22)

						3)CARE A (RWN) (06-Jun-24)	2)CARE A+; Negative (05-Oct-23) 3)CARE A+; Negative (16-May-23)	
12	Debt-Subordinate Debt	LT	-	-	-	1)CARE A; Stable (11-Feb-25) 2)CARE A (RWN) (08-Oct-24) 3)CARE A (RWN) (06-Jun-24)	1)CARE A; Stable (03-Jan-24) 2)CARE A+; Negative (05-Oct-23) 3)CARE A+; Negative (16-May-23)	-
13	Debentures-Non-convertible debentures	LT	100.00	CARE A; Stable				
14	Debt-Subordinate Debt	LT	112.00	CARE A; Stable				

LT: Long term; ST: Short term

Annexure-3: Detailed explanation of covenants of rated instruments/facilities – Not applicable

Annexure-4: Complexity level of instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Debentures-Non-convertible debentures	Simple
2	Debt-Subordinate Debt	Complex
3	Fund-based-Long Term	Simple

Annexure-5: Lender details

To view lender-wise details of bank facilities please click here

Annexure-6: List of entities consolidated

Sr No	Name of the entity	Extent of consolidation	Rationale for consolidation
1	ECL Finance Limited	Full	Subsidiary
2	Edelcap Securities Limited	Full	Subsidiary
3	Edelweiss Asset Management Limited	Full	Subsidiary
4	Ecap Securities & Investments Ltd	Full	Subsidiary
5	Edelweiss Trusteeship Company Limited	Full	Subsidiary
6	Nido Home Finance Limited	Full	Subsidiary
7	Edelweiss Investment Advisors Private Limited, Singapore	Full	Subsidiary
8	Ecap Equities Limited	Full	Subsidiary
9	Edel Investments Limited	Full	Subsidiary
10	Edelweiss Rural & Corporate Services Limited	Full	Subsidiary
11	Comtrade Commodities Services Ltd	Full	Subsidiary
12	Edel Finance Company Ltd.	Full	Subsidiary
13	Edelweiss Retail Finance Limited	Full	Subsidiary
14	Zuno General Insurance Limited	Full	Subsidiary
15	Edelweiss Securities and Investments Pvt Ltd	Full	Subsidiary
16	EAAA Pte. Limited (formerly known as Edelweiss Alternative Asset Advisors Pte. Limited)	Full	Subsidiary
17	Edelweiss International (Singapore) Pte. Limited	Full	Subsidiary
18	Edelgive Foundation	Full	Subsidiary
19	Edelweiss Alternative Asset Advisors Limited (formerly known as Edelweiss Alternative Asset Advisors Limited)	Full	Subsidiary
20	Edelweiss Asset Reconstruction Company Limited	Full	Subsidiary
21	Edelweiss Life Insurance Company Limited (formerly known as Edelweiss Tokio Life Insurance Company Limited)	Full	Subsidiary
22	Allium Corporate Services Private Limited (formerly known as Allium Finance Private Limited)	Full	Subsidiary
23	Edelweiss Global Wealth Management Limited	Full	Subsidiary
24	Nuvama Custodial Services Limited	Full	Subsidiary
25	EAAA Real Assets Managers Limited (formerly known as Edelweiss Real Assets Managers Limited)	Full	Subsidiary
26	Sekura India Management Limited	Full	Subsidiary
27	EAAA Transinfra Manager Limited	Full	Subsidiary

Note on complexity levels of rated instruments: CareEdge Ratings has classified instruments rated by it based on complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for clarifications.

Contact us

Media Contact	**Analytical Contacts**
Mradul Mishra Director **CARE Ratings Limited** Phone: +91-22-6754 3596 E-mail: mradul.mishra@careedge.in **Relationship Contact** Pradeep Kumar V Senior Director **CARE Ratings Limited** Phone: 044-28501001 E-mail: pradeep.kumar@careedge.in	Vineet Jain Senior Director **CARE Ratings Limited** Phone: +91-22-6754 3623 E-mail: vineet.jain@careedge.in Akansha Manohar Jain Assistant Director **CARE Ratings Limited** Phone: +91-22-6754 3491 E-mail: akansha.jain@careedge.in Shubham Deokar Lead Analyst **CARE Ratings Limited** E-mail: Shubham.Deokar@careedge.in

About us:

Established in 1993, CareEdge Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the Reserve Bank of India. With an equitable position in the Indian capital market, CareEdge Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CareEdge Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CareEdge Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit. For more information: www.careratings.com

Disclaimer:

This disclaimer pertains to the ratings issued and content published by CARE Ratings Limited ("CareEdge Ratings"). Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. Any opinions expressed herein are in good faith and are subject to change without notice. The rating reflects the opinions as on the date of the rating. A rating does not convey suitability or price for the investor. The rating agency does not conduct an audit on the rated entity or an independent verification of any information it receives and/or relies on for the rating exercise. CareEdge Ratings has based its ratings/outlook on the information obtained from reliable and credible sources. CareEdge Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. The users of the rating should rely on their own judgment and may take professional advice while using the rating in any way. CareEdge Ratings shall not be liable for any losses that user may incur or any financial liability whatsoever to the user of the rating. The use or access of the rating does not create a client relationship between CareEdge Ratings and the user.

CAREEDGE RATINGS DISCLAIMS WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR OTHER WARRANTIES OR CONDITIONS, TO THE EXTENT PERMITTED BY APPLICABLE LAWS, INCLUDING WARRANTIES OF MERCHANTABILITY, ACCURACY, COMPLETENESS, ERROR-FREE, NON-INFRINGEMENT, NON-INTERRUPTION, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE OR INTENDED USAGE.

Most entities whose bank facilities/instruments are rated by CareEdge Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CareEdge Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. CareEdge Ratings does not act as a fiduciary by providing the rating. The ratings are intended for use only within the jurisdiction of India. The ratings of CareEdge Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades. CareEdge Ratings has established policies and procedures as required under applicable laws and regulations which are available on its website.

Privacy Policy applies. For Privacy Policy please refer to https://www.careratings.com/privacy_policy

© 2025, CARE Ratings Limited. All Rights Reserved.

This content is being published for the purpose of dissemination of information. Any use or reference to the contents herein on an "as-is" basis is permitted with due acknowledgement to CARE Ratings. Reproduction or retransmission in whole or in part is prohibited except with prior written consent from CARE Ratings.

For detailed Rating Report and subscription information, please visit www.careratings.com